$PODD
INSULET CORP

2014 Q3 Form 10-Q Financial Statement

#000114519714000042 Filed on August 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q4
Revenue $60.03M $57.58M $68.53M
YoY Change -1.76% -4.19% 18.51%
Cost Of Revenue $36.94M $36.25M $35.50M
YoY Change 9.6% 8.99% 9.23%
Gross Profit $33.74M $31.83M $33.02M
YoY Change 23.17% 18.63% 30.41%
Gross Profit Margin 56.21% 55.28% 48.18%
Selling, General & Admin $33.76M $34.37M $26.40M
YoY Change -13.3% 25.06% 3.13%
% of Gross Profit 100.05% 107.97% 79.96%
Research & Development $7.158M $6.677M $6.400M
YoY Change 24.03% 29.05% 10.34%
% of Gross Profit 21.21% 20.98% 19.38%
Depreciation & Amortization $3.070M $3.030M $2.950M
YoY Change -0.97% 5.94% 0.34%
% of Gross Profit 9.1% 9.52% 8.93%
Operating Expenses $40.92M $41.05M $32.80M
YoY Change -8.48% 25.69% 4.46%
Operating Profit -$2.876M -$5.280M $218.0K
YoY Change -83.39% -9.31% -103.58%
Interest Expense -$3.700M $300.0K -$2.900M
YoY Change -3800.0% -27.5%
% of Operating Profit -1330.28%
Other Income/Expense, Net -$7.948M -$23.78M
YoY Change 100.1% 419.31%
Pretax Income -$10.82M -$29.06M -$2.700M
YoY Change -49.15% 179.39% -73.27%
Income Tax $21.00K $52.00K -$200.0K
% Of Pretax Income
Net Earnings -$10.85M -$29.11M -$2.500M
YoY Change -49.06% 176.75% -75.48%
Net Earnings / Revenue -18.07% -50.56% -3.65%
Basic Earnings Per Share
Diluted Earnings Per Share -$193.5K -$525.3K -$45.70K
COMMON SHARES
Basic Shares Outstanding 55.88M shares 55.41M shares 54.54M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $146.4M $175.5M $149.7M
YoY Change -4.87% 16.3% 161.26%
Cash & Equivalents $146.4M $175.5M $149.7M
Short-Term Investments
Other Short-Term Assets $3.400M $5.700M $5.900M
YoY Change -42.37% -13.64% 31.11%
Inventory $9.662M $8.765M $9.464M
Prepaid Expenses
Receivables $47.15M $41.80M $33.07M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $206.6M $231.8M $198.2M
YoY Change 3.47% 17.6% 80.28%
LONG-TERM ASSETS
Property, Plant & Equipment $36.58M $34.16M $32.36M
YoY Change 16.51% 16.45% 27.28%
Goodwill $37.54M $37.54M $37.40M
YoY Change 0.0% 0.0% -0.37%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.493M $5.919M $1.825M
YoY Change 219.17% 213.84% -17.12%
Total Long-Term Assets $94.58M $93.50M $89.76M
YoY Change 5.32% 5.02% 1.85%
TOTAL ASSETS
Total Short-Term Assets $206.6M $231.8M $198.2M
Total Long-Term Assets $94.58M $93.50M $89.76M
Total Assets $301.2M $325.3M $288.0M
YoY Change 4.04% 13.69% 45.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.73M $18.61M $19.36M
YoY Change 17.26% 62.66% 106.8%
Accrued Expenses $25.21M $24.59M $19.48M
YoY Change -16.0% 21.27% 2.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.000M $23.87M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $47.76M $71.20M $42.37M
YoY Change -1.1% 110.32% -12.24%
LONG-TERM LIABILITIES
Long-Term Debt $167.4M $165.9M $113.7M
YoY Change 50.67% 52.64% 9.56%
Other Long-Term Liabilities $2.580M $1.521M $1.943M
YoY Change 0.51% -32.28% 4.07%
Total Long-Term Liabilities $170.0M $167.4M $115.6M
YoY Change 49.54% 50.92% 9.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.76M $71.20M $42.37M
Total Long-Term Liabilities $170.0M $167.4M $115.6M
Total Liabilities $220.9M $242.5M $163.4M
YoY Change 31.41% 64.04% 6.16%
SHAREHOLDERS EQUITY
Retained Earnings -$572.6M -$561.8M -$526.5M
YoY Change 9.27% 11.74% 9.34%
Common Stock $56.00K $55.00K $55.00K
YoY Change 1.82% 1.85% 14.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.34M $77.88M $124.6M
YoY Change
Total Liabilities & Shareholders Equity $301.2M $325.3M $288.0M
YoY Change 4.04% 13.69% 45.39%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q4
OPERATING ACTIVITIES
Net Income -$10.85M -$29.11M -$2.500M
YoY Change -49.06% 176.75% -75.48%
Depreciation, Depletion And Amortization $3.070M $3.030M $2.950M
YoY Change -0.97% 5.94% 0.34%
Cash From Operating Activities $4.820M $510.0K -$3.520M
YoY Change 30.27% -88.33% -37.03%
INVESTING ACTIVITIES
Capital Expenditures -$3.100M -$3.590M -$2.790M
YoY Change 70.33% 120.25% 36.1%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$3.100M -$3.590M -$2.790M
YoY Change 70.33% 120.25% 36.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.88M 33.01M 2.130M
YoY Change -2933.03% 25292.31% 42.0%
NET CHANGE
Cash From Operating Activities 4.820M 510.0K -3.520M
Cash From Investing Activities -3.100M -3.590M -2.790M
Cash From Financing Activities -30.88M 33.01M 2.130M
Net Change In Cash -29.16M 29.93M -4.180M
YoY Change -1081.82% 942.86% -31.92%
FREE CASH FLOW
Cash From Operating Activities $4.820M $510.0K -$3.520M
Capital Expenditures -$3.100M -$3.590M -$2.790M
Free Cash Flow $7.920M $4.100M -$730.0K
YoY Change 43.48% -31.67% -79.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
192000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
338000 USD
CY2013Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
149000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
297000 USD
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
639609000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5869000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5808000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2200000 USD
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P8Y
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19359000 USD
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
18610000 USD
CY2013Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
40200000 USD
CY2014Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
48542000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33067000 USD
CY2014Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
41797000 USD
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24588000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19478000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
651067000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6800000 USD
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4200000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8600000 USD
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3800000 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7133000 USD
CY2014Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6745000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5511000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4883000 USD
CY2013Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2751000 USD
CY2014Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2258000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2700000 USD
CY2014Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
CY2013Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9594181 shares
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8030735 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8030735 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9594181 shares
CY2013Q4 us-gaap Assets
Assets
287955000 USD
CY2014Q2 us-gaap Assets
Assets
325328000 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
231832000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
198198000 USD
CY2014Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2872000 USD
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2637000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
4284000 USD
CY2014Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
3893000 USD
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
5390000 USD
CY2014Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
8131000 USD
CY2014Q2 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
3815000 USD
CY2014Q2 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
2409000 USD
CY2014Q2 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
1366000 USD
CY2014Q2 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
6765000 USD
CY2014Q2 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1907000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149727000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175545000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150944000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57293000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
123129000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
128308000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25818000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
93651000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54870424 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55495352 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54870424 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55495352 shares
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2013 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.36
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.29
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
65460000 USD
CY2013Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33259000 USD
CY2014Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36248000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
72601000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
191000 USD
CY2013Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
88000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
53000 USD
CY2014Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
22000 USD
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
620122 shares
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
26523 shares
CY2013Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
30099000 USD
CY2014Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
40342000 USD
CY2014Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
5638000 USD
CY2013Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1414000 USD
CY2014Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
30000 USD
CY2013Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
30000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
58000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
64000 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
900000 USD
CY2014Q2 us-gaap Deferred Revenue
DeferredRevenue
1300000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
900000 USD
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1255000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6100000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5763000 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
36500000 USD
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0041
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y5M15D
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y0M12D
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.3800
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.3530
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0056
CY2014Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17018000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14860000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
4151000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3251000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1819000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1806000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2190000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2665000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18040000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15882000 USD
CY2011 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
32900000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-18943000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-325000 USD
CY2013Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-325000 USD
CY2014Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-18943000 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19512000 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13901000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33771000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26995000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
37536000 USD
CY2014Q2 us-gaap Goodwill
Goodwill
37536000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2014Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2013Q2 us-gaap Gross Profit
GrossProfit
26833000 USD
us-gaap Gross Profit
GrossProfit
68573000 USD
us-gaap Gross Profit
GrossProfit
51988000 USD
CY2014Q2 us-gaap Gross Profit
GrossProfit
35765000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20935000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-35138000 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10401000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-29059000 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
118000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
249000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
117000 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10534000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2924000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4545000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
355000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-8888000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-699000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-422000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
379000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1006000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2055000 USD
CY2014Q2 us-gaap Interest Expense
InterestExpense
300000 USD
us-gaap Interest Expense
InterestExpense
600000 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2014Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
3975000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
8464000 USD
CY2013Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4291000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
8646000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7394000 USD
CY2014Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6992000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
9464000 USD
CY2014Q2 us-gaap Inventory Net
InventoryNet
8765000 USD
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
399000 USD
CY2014Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
917000 USD
CY2014Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
856000 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1671000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
60000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
64000 USD
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000 USD
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000 USD
CY2014Q2 us-gaap Liabilities
Liabilities
242483000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
163358000 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
325328000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287955000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42374000 USD
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
71199000 USD
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
7000000 USD
CY2014Q2 us-gaap Long Term Debt
LongTermDebt
189744000 USD
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
113651000 USD
CY2014Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
23874000 USD
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2014Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
165870000 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
113651000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of the Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the &#8220;OmniPod System&#8221;), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the only commercially-available insulin infusion system of its kind. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (&#8220;PDM&#8221;). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:inherit;font-size:10pt;"> inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#8220;Neighborhood Diabetes&#8221;) in order to expand the Company&#8217;s full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began commercial sale of the OmniPod System in the United States in October 2005. The Company has also expanded the availability of the OmniPod System internationally through its partnerships with Ypsomed Distribution AG (&#8220;Ypsomed&#8221;) and GlaxoSmithKline (&#8220;GSK&#8221;). In August 2011, the Company received CE Mark approval, and in December 2012, the Company received 510(k) clearance for the new OmniPod System from the FDA. The Company began selling its new OmniPod System in 2013. The new OmniPod System is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities.</font></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93174000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32072000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5745000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2695000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-509000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3172000 USD
us-gaap Net Income Loss
NetIncomeLoss
-21184000 USD
us-gaap Net Income Loss
NetIncomeLoss
-35255000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-10519000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-29111000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27972000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5822000 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4579000 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23779000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8907000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Operating Expenses
OperatingExpenses
64016000 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
32655000 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
41045000 USD
us-gaap Operating Expenses
OperatingExpenses
75739000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7166000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12028000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5280000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
17461000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2096000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2144000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2139000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2057000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
8249000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
776000 USD
CY2014Q2 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
702000 USD
CY2013Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
1351000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1825000 USD
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5919000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1943000 USD
CY2014Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1521000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-625000 USD
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-890000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5890000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2431000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2695000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5745000 USD
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5725000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5940000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5339000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
97605000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
194570000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2013Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3090000 USD
CY2014Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2505000 USD
CY2013Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2401000 USD
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1992000 USD
CY2013Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2249000 USD
CY2014Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3100000 USD
CY2014Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
994000 USD
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1173000 USD
CY2013Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1917000 USD
CY2014Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1511000 USD
CY2014Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
445000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1252000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1127000 USD
CY2013Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
633000 USD
CY2014Q2 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
-150000 USD
CY2013Q2 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
785000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
542000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1661000 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34159000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32356000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2568000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1804000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
160685000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1262000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6677000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9570000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5174000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13456000 USD
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-561780000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-526525000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
141174000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
117448000 USD
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
72013000 USD
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
60092000 USD
CY2013Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13580000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28512000 USD
CY2014Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14856000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27451000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6844000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8577000 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2544999 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
923061 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11615000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
18158 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
227500 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
31509000 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1634584 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1828613 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.97
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.46
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
27826000 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1370909 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.70
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
23.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
42.67
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55425949 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55258419 shares
CY2013Q4 us-gaap Share Price
SharePrice
37.10
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
22523000 USD
CY2014Q2 us-gaap Share Price
SharePrice
39.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y0M0D
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
13000000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
403371 shares
CY2013Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
97800000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
77884000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
124597000 USD
CY2014Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue, debt instruments, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53834707 shares
CY2014Q2 podd Changein Fair Valueof Call Option Feature
ChangeinFairValueofCallOptionFeature
900000 USD
CY2014Q2 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2013Q2 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1460000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53445715 shares
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
3009000 USD
CY2013Q4 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
podd Allocationtoequityforconversionforthe2 Notes
Allocationtoequityforconversionforthe2Notes
0 USD
podd Allocationtoequityforconversionforthe2 Notes
Allocationtoequityforconversionforthe2Notes
35638000 USD
CY2014Q2 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1273000 USD
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
2621000 USD
CY2014Q2 podd Number Of Financial Institution
NumberOfFinancialInstitution
2 location
CY2014Q2 podd Number Of Inches Of Tubing In Conventional Insulin Pump
NumberOfInchesOfTubingInConventionalInsulinPump
42 in
CY2014Q2 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2014Q2 podd Amountallocatedtodebt
Amountallocatedtodebt
112400000 USD
CY2014Q2 podd Amountallocatedtoequity
Amountallocatedtoequity
48300000 USD
podd Interestand Other Expense Total
InterestandOtherExpenseTotal
9142000 USD
CY2013 podd Capital Leasesof Lessee Contingent Rentals Effective Interest Rate
CapitalLeasesofLesseeContingentRentalsEffectiveInterestRate
0.17
podd Changein Fair Valueof Call Option Feature
ChangeinFairValueofCallOptionFeature
600000 USD
CY2014Q2 podd Fair Value Assumption Bond Call Strike Price
FairValueAssumptionBondCallStrikePrice
100.00
CY2013Q4 podd Fair Value Assumption Bond Call Strike Price
FairValueAssumptionBondCallStrikePrice
100.00
podd Fair Value Assumption Conversion Price
FairValueAssumptionConversionPrice
26.20
CY2013 podd Fair Value Assumption Conversion Price
FairValueAssumptionConversionPrice
26.20
podd Fair Value Assumption Coupon Rate
FairValueAssumptionCouponRate
0.0375
CY2013 podd Fair Value Assumption Coupon Rate
FairValueAssumptionCouponRate
0.0375
CY2013 podd Fair Value Assumptions Bond Yield
FairValueAssumptionsBondYield
0.0861
podd Fair Value Assumptions Bond Yield
FairValueAssumptionsBondYield
0.0491
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
3305000 USD
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
4361000 USD
CY2013Q2 podd Interestand Other Expense Total
InterestandOtherExpenseTotal
4685000 USD
CY2014Q2 podd Interestand Other Expense Total
InterestandOtherExpenseTotal
22666000 USD
podd Interestand Other Expense Total
InterestandOtherExpenseTotal
26785000 USD
CY2013Q4 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
podd Product Warranty Term
ProductWarrantyTerm
P4Y
CY2013 podd Repayment Periodfor Capital Lease Obligations
RepaymentPeriodforCapitalLeaseObligations
P36M
podd Return Period
ReturnPeriod
P45D
podd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitures
0.16
podd Stock Price Change Percent
StockPriceChangePercent
0.07
CY2014Q2 podd Temporary Equity Redeemableconvertibledebt
TemporaryEquityRedeemableconvertibledebt
4961000 USD
CY2013Q4 podd Temporary Equity Redeemableconvertibledebt
TemporaryEquityRedeemableconvertibledebt
0 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55881647 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
dei Trading Symbol
TradingSymbol
PODD

Files In Submission

Name View Source Status
0001145197-14-000042-index-headers.html Edgar Link pending
0001145197-14-000042-index.html Edgar Link pending
0001145197-14-000042.txt Edgar Link pending
0001145197-14-000042-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
podd-20140630.xml Edgar Link completed
podd-20140630.xsd Edgar Link pending
podd-20140630_cal.xml Edgar Link unprocessable
podd-20140630_def.xml Edgar Link unprocessable
podd-20140630_lab.xml Edgar Link unprocessable
podd-20140630_pre.xml Edgar Link unprocessable
podd-2014x06x30_10xq.htm Edgar Link pending
podd-ex101_20140630x10q.htm Edgar Link pending
podd-ex102_20140630x10q.htm Edgar Link pending
podd-ex103_20140630x10q.htm Edgar Link pending
podd-ex311_20140330x10q.htm Edgar Link pending
podd-ex312_20140630x10q.htm Edgar Link pending
podd-ex321_20140630x10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending